BPC-157 / TB-500 blend
Pre-mixed lyophilised combination of BPC-157 and TB-500 in a 1:1 ratio by mass (5 mg + 5 mg or 10 mg + 10 mg per vial).
Prepared to order · approx. 7 days + Royal Mail Tracked 24
SKU BP-BPCTB-10 · ≥99% (see COA) · Lyophilised powder
Note: Components and ratio taken from the supplier list ("BPC 5mg + TB 5mg; BPC 10mg + TB 10mg"). Confirm the per-component content from the batch COA.
BPC-157 / TB-500 blend overview
Each vial contains BPC-157 and TB-500 in equal amounts by mass (5 mg + 5 mg in the 10 mg size, 10 mg + 10 mg in the 20 mg size), co-lyophilised, per the supplier specification. See the individual component pages for data. Supplied for in-vitro laboratory research only.
BPC-157 / TB-500 blend research background
Evidence status: This combination has not been studied as a blend; findings summarised here relate to the individual components, much of it preclinical (cell or animal) or small-scale. They are not established effects in humans, have not been evaluated by the MHRA, and are provided for scientific context only. This product is supplied strictly for laboratory research and is not for human or veterinary use.
BPC-157
BPC-157 is a synthetic 15-amino-acid peptide whose sequence was described as a partial sequence of a protein ('body protection compound') isolated from gastric juice. Most of the published work comes from a single research group, and reviews have noted that independent replication is limited [1][2].
TB-500 (Thymosin β4)
'TB-500' is a commercial name rather than a defined scientific compound. It is used both for synthetic full-length thymosin β4 (Tβ4, 43 amino acids) and for short fragments containing the actin-binding motif LKKTETQ (residues 17–23). For example, one registered clinical trial describes 'TB-500' as the thymosin β4 17–23 fragment (NCT07487363). The identity of this product must be confirmed from the batch COA.
Established research
Peer-reviewed published findings, with referencesOverview & discovery history
- This research blend combines 2 separately characterised compounds. The combination itself has not been studied in peer-reviewed research; the summaries below relate to each component individually. See each component's own product page for its full research background.
Chemical identity
Identity values are confirmed per lot on the certificate of analysis. Salt/counter-ion form (e.g. acetate or TFA) is stated on the COA where applicable.
Mechanisms investigated
Research areas & model types
| Research area | Model type | Summary |
|---|---|---|
| BPC-157 – Tendon and ligament injury models | Rodent; in vitro | Rat Achilles-tendon transection and tendon-fibroblast culture studies [9][10]; summarised in reviews of musculoskeletal soft-tissue research [1]. |
| BPC-157 – Angiogenesis and vascular models | In vitro; rodent | Chick chorioallantoic membrane assay, endothelial tube formation and rat hind-limb ischaemia [11]. |
| TB-500 (Thymosin β4) – Dermal wound models | Rodent; in vitro | Rat full-thickness wound model and keratinocyte migration assays [12]. |
| TB-500 (Thymosin β4) – Cardiac injury models | Mouse; in vitro | Coronary-artery ligation in mice and cardiomyocyte culture [13]. |
Human clinical research status
- No studies of this combination were identified. Clinical-status notes for individual components are summarised below; they do not apply to the blend.
- BPC-157: No completed, published randomised controlled trial of BPC-157 was identified. A 2025 systematic review in orthopaedic sports medicine found only level IV–V evidence (case series and similar reports) in humans and reported that no clinical safety data were found [5].
- TB-500 (Thymosin β4): Full-length Tβ4 (as investigational formulations) has been studied in Phase 2 trials in dry eye [6][7] and venous stasis ulcers [8]. Thymosin β4 is not an approved medicine in the UK, the US or the EU.
Safety observations reported in studies
- No safety data exist for the combination. Interactions between components have not been studied.
Known limitations
- The combination has not been studied; whether the components interact chemically or biologically in solution is unknown.
Storage & handling for laboratory use
Store at −20 °C. Protect from light.
Store lyophilised material sealed at −20 °C or below, protected from light and moisture. Allow the vial to equilibrate to room temperature before opening to limit condensation.
- Allow the sealed vial to reach room temperature before opening to limit condensation.
- Any solutions should be prepared only for in-vitro laboratory work under your own validated protocol; aliquoting limits repeated freeze–thaw cycles.
- Handle with standard laboratory PPE in line with your risk assessment and the Safety Data Sheet (SDS). Britpep does not provide preparation or administration guidance.
Emerging & theoretical
Unconfirmed — hypotheses & ongoing researchThese are unconfirmed hypotheses and early-stage lines of enquiry, not established effects. Not evaluated by the MHRA. Not for human or veterinary use.
Hypotheses proposed by researchers
- BPC-157: Researchers have proposed that BPC-157 acts as a modulator of the NO system and of angiogenic signalling, which would link its varied reported effects in animal models [3][11].
- TB-500 (Thymosin β4): Researchers have proposed that distinct Tβ4 activities sit in separate short sequences, which could allow fragment-based research tools [14].
Registered clinical studies (ongoing or unpublished)
- NCT07437547 — BPC-157 (component, not the blend): Phase 2 randomised, placebo-controlled trial in acute grade II hamstring strain (sponsor: Hudson Biotech). Listed as recruiting.
- NCT07803250 — BPC-157 (component, not the blend): Phase 1 study in recovery after rotator-cuff repair surgery (sponsor: University of Arkansas). Listed as not yet recruiting.
- NCT07487363 — TB-500 (Thymosin β4) (component, not the blend): Phase 1/2 dose-escalation study of 'TB-500 (thymosin β4 17–23 fragment)' in stable atherosclerotic cardiovascular disease (sponsor: Hudson Biotech). Listed as recruiting.
- NCT05555589 — TB-500 (Thymosin β4) (component, not the blend): Phase 3 SEER-2 trial of RGN-259 (thymosin β4) in neurotrophic keratopathy (sponsor: ReGenTree). Listed as recruiting.
- NCT07586865 — TB-500 (Thymosin β4) (component, not the blend): Phase IIc trial of recombinant human thymosin β4 (NL005) in acute myocardial infarction (sponsor: Beijing Northland Biotech). Listed as not yet recruiting.
Registry entries checked on ClinicalTrials.gov on 24 October 2026; status as listed by the sponsor. Registration does not imply results or efficacy.
Open scientific questions
- Whether the components are chemically compatible and stable when combined has not been reported.
Preprints: none included (no relevant preprint could be verified). Anecdotal, user-reported or social-media material is deliberately excluded.
References
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019. PubMed 30915550 · doi:10.1007/s00441-019-03016-8
- McGuire FP, Martinez R, Lenz A et al.. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. PubMed 40789979 · doi:10.1007/s12178-025-09990-7
- Sikiric P, Seiwerth S, Rucman R et al.. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014. PubMed 23755725 · doi:10.2174/13816128113190990411
- Cassimeris L, Safer D, Nachmias VT et al.. Thymosin beta 4 sequesters the majority of G-actin in resting human polymorphonuclear leukocytes. J Cell Biol. 1992. PubMed 1447300 · doi:10.1083/jcb.119.5.1261
- Vasireddi N, Hahamyan H, Salata MJ et al.. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PubMed 40756949 · doi:10.1177/15563316251355551
- Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015. PubMed 25826322 · doi:10.1097/ICO.0000000000000379
- Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015. PubMed 26056426 · doi:10.2147/OPTH.S80954
- Guarnera G, DeRosa A, Camerini R. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010. PubMed 20536470 · doi:10.1111/j.1749-6632.2010.05490.x
- Staresinic M, Sebecic B, Patrlj L et al.. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003. PubMed 14554208 · doi:10.1016/S0736-0266(03)00110-4
- Chang CH, Tsai WC, Lin MS et al.. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011. PubMed 21030672 · doi:10.1152/japplphysiol.00945.2010
- Hsieh MJ, Liu HT, Wang CN et al.. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017. PubMed 27847966 · doi:10.1007/s00109-016-1488-y
- Malinda KM, Sidhu GS, Mani H et al.. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. PubMed 10469335 · doi:10.1046/j.1523-1747.1999.00708.x
- Bock-Marquette I, Saxena A, White MD et al.. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004. PubMed 15565145 · doi:10.1038/nature03000
- Sosne G, Qiu P, Goldstein AL et al.. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010. PubMed 20179146 · doi:10.1096/fj.09-142307
Every reference was checked against PubMed (NCBI) before publication. Summaries describe published research only and are not claims of any effect in humans or animals.
Certificates of analysis
[No batch COA published yet. The certificate for each lot will be listed here and in the COA checker before release.]
Related research compounds
BPC-157
BPC-157 / GHK-Cu / TB-500 blend
TB-500 (Thymosin β4)
BPC-157 / GHK-Cu / TB-500 / KPV blend
Browse similar compounds: Cell-signalling research peptides, Research peptide blends or the full catalogue.